



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Tetsuo NAGANO et al.

Group Art Unit : 1743

Appln. No. : 10/744,007

Examiner : Unknown

Filed : December 24, 2003

For : DIAMINORHODAMINE DERIVATIVE

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir :

In accordance with Applicants' duty of disclosure under 37 C.F.R. 1.56, Applicants hereby submit the following Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98, and in conformance with MPEP 609 and 37 C.F.R. 1.98(d).

Applicants hereby make of record the disclosure statement filed August 20, 2001, and the Information cited by the Examiner in the Office Action mailed February 4, 2003 in parent Application No. 09/641,350.

The Examiner is respectfully requested to consider the documents cited in the parent application, and to make the documents cited therein of record in the instant application.

Applicants note that copies of documents cited in the above-mentioned disclosure statement have been submitted in parent Application No. 09/641,350. Accordingly, pursuant to 37 C.F.R. 1.98(d) copies of the documents are not being submitted herewith, and the Examiner is invited to review and consider the documents in the parent application. Of course, should any of the


P24350.A01

documents not be readily available to the Examiner, the Examiner is requested to contact the undersigned and additional copies will be submitted.

For the convenience of the Examiner, the above-noted documents cited in the parent applications are listed on the attached Forms PTO-1449. The Examiner is requested to initial the Forms PTO-1449, and to return the initialed copy with the next communication from the U.S. Patent and Trademark Office.

Should the Examiner have any questions or comments regarding this matter, the undersigned may be contacted at the below-listed telephone number.

Respectfully submitted,  
Tetsuo NAGANO et al.



Bruce H. Bernstein  
Reg. No. 29,027

*Regno 33,087*

March 24, 2004  
GREENBLUM & BERNSTEIN, P.L.C.  
1950 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191



Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
P24350Serial No.  
10/744,007

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)

Applicant  
Tetsuo NAGANO et al.Filing Date  
December 24, 2003Group  
1743

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5 8 7 4 5 9 0	02/23/99	NAGANO et al.			
	6 2 0 1 1 3 4	03/2001	NAGANO et al.			
	6 4 6 9 0 5 1	10/2002	NAGANO et al.			

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
9 - 0 4 3 1 5 3	02/14/97	JAPAN			
1 0 2 2 6 6 8 8	08/25/98	JAPAN			
9 9 / 0 1 4 4 7	01/14/99	W.I.P.O.			
0 1 / 6 3 2 6 5	08/2001	W.I.P.O.			


## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1	English Language Abstract of JP 9-043153
2	English Language Abstract of JP 10-226688
3	Chemistry Today [Gendai Kagaku], April, pp. 25-29 (1994).
4	PALMER et al., <u>Nature</u> , Vol. 327, pp. 524-526 (1987).
5	KELM et al., <u>Circulation Research</u> , Vol. 66, No. 6, pp. 1561-1575 (1990).
6	SHIBUKI, <u>Neuroscience Research</u> 9, pp. 69-76 (1990).
7	MALINSKI et al., <u>Nature</u> , Vol. 358, pp. 676-678 (1992).
8	GREEN et al., <u>Analytical Biochemistry</u> , Vol. 126, pp. 131-138 (1982).
9	"Approaches From The Newest Medicine [Saishin Igaku Kara No Approach] 12, NO", Ed. by Noboru Toda, pp. 42-52.
1 0	ARCHER, <u>The FASEB Journal</u> , Vol.7, pp. 349-360 (1993).
1 1	STANTON, <u>Analytical Chemistry</u> , Vol. 46, No. 11, p. 1616, (1974).
1 2	SAWICKI et al., <u>Microchemical Journal</u> , Vol. 16, pp. 657-672 (1971).
1 3	WIERSMA, <u>Analytical Letters</u> , Vol. 3, No. 3, pp. 123-132 (1970).
1 4	DAMIANI, <u>Talanta</u> , Vol. 33, No. 8, pp. 649-652 (1986).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Group  
1743

## DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.